Main navigation

• Home
• About us
• Medicines
• Research
• Careers
• Responsibility
• Partnering
• Media
• Investors
  • Shareholder information
  • Investor tools
  • Directors' shareholdings
  • SEC filings
  • Financial calendar
  • Financial results
  • Annual reports
  • Presentations & webcasts
  • Financial highlights
  • Strategy
  • FAQs
  • Investor contacts

You are here

• Home

• Investor relations

• Latest news collapse

  • 09 February 2010 US FDA Approves New Indication for Crestor (Rosuvastatin Calcium)

    AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved CRESTOR (rosuvastatin calcium) to reduce the risk of stroke, myocardial infarction (heart attack) and arterial revascularization procedures in individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD).

  more news

  • previous
  • • 1
    • 2
    • 3
    • 4
    • 5
  • next

  Research & Development collapse

  We focus our research on six disease areas where we believe our skills and experience can make the most difference.

  • Read about our disease area focus
  • Review our pipeline summary

  Share price tools collapse

  • Interactive stock charts
  • Share holding calculator
  • Share price look-up
  • Share price history

• Currency Guidance 2010 collapse

  • View 2010 currency guidance

  Annual Report 2008 collapse

  • Online annual report
  • Order a printed copy

  Latest presentation collapse

  February 2010
  

  • Investor Relations general presentation (PDF 3 Mb)

  • Other presentations

  Financial results collapse

  Fourth quarter and full year results 2009 announced on Thursday 28th January.

  • View details of the event
  • View financial calendar

  Managing your shares collapse

  • Dividend information
  • Shareholder forms
  • Share registration contacts
  • Annual General Meeting
  • FAQs

Not signed in

Page tools

• Print
• Bookmark this page

Share price